Skip to main content

Table 1 Patient characteristics at baseline (6 months pre-index)

From: Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy

Characteristic Total (N =4,156) Monotherapy (n =3,188) Polypharmacy (n =968) p-value a
Length of follow-up, days (mean, SD) 993.5 (391.8) 989.3 (393.8) 999.3 (397.1) .488
Gender, n (%)     
  Male 2206 (53.1) 1,710 (53.6) 496 (51.2) .190
Age at index date, years (mean, SD) 40 (13.7) 40.3 (13.6) 37.8 (13.6) <.001
Psychiatric comorbidities, n (%)     
  Depression 1090 (26.2) 806 (25.3) 284 (29.3) .012
  Schizoaffective disorders 991 (23.8) 786 (24.7) 205 (21.2) .026
  Anxiety disorders 441 (10.6) 336 (10.5) 105 (10.8) .786
  Bipolar disorder 247 (5.9) 190 (6.0) 57 (5.9) .934
  Personality disorders 128 (3.1) 94 (2.9) 34 (3.5) .374
  Attention deficit disorder 114 (2.7) 83 (2.6) 31 (3.2) .318
  Substance use disorder 83 (2.0) 59 (1.9) 24 (2.5) .221
Psychiatric medications, n (%)     
  Antidepressants 2016 (48.5) 1516 (47.6) 500 (51.7) .025
  Sedatives or hypnotics 1623 (39.1) 1051 (33.0) 572 (40.9) <.001
  Mood stabilizers 1073 (25.8) 794 (24.9) 279 (28.8) .015
  Anti-anxiety medications 926 (22.3) 678 (21.3) 248 (25.6) .004
  Stimulants and ADHD medications 40 (1.0) 32 (1.0) 8 (0.8) .621
Mean (SD) Deyo-Charlson Comorbidity Index Score (range 0–16) 0.6 (1.0) 0.6 (1.0) 0.6 (0.9) .546
Somatic medications, n (%)     
  Anti-hyperlipidemic agents 623 (15.0) 490 (15.4) 133 (13.7) .213
  Anti-hypertensive agents 502 (12.1) 408 (12.8) 94 (9.7) .010
  Anti-thyroid agents 418 (10.1) 310 (9.7) 108 (11.2) .194
  Anti-diabetic agents 358 (8.6) 275 (8.6) 83 (8.6) .960
  Anti-Parkinson agents 60 (1.4) 37 (1.2) 23 (2.4) .005
Random sample of patients with baseline disease severity data available from charts (n = 121), n (%)     
  Mild 25 (20.7) 22 (23.2) 3 (11.5)  
  Moderate 31 (25.6) 25 (26.3) 6 (23.1)  
  Severe 65 (53.7) 48 (50.5) 17 (65.5)  
  1. ADHD = attention deficit hyperactivity disorder; SD = standard deviation.
  2. aPolypharmacy vs monotherapy.